An Australia-first comparison of FDA and TGA requirements for sponsors. Practical ARTG steps, calibration record checks and PCS Precision support to...
The Therapeutic Goods Administration governs therapeutic goods supplied in Australia, while the FDA is the United States regulator with no direct authority here. Most therapeutic goods sold in Australia must be authorised and listed on the Australian Register of Therapeutic Goods, regardless of any FDA clearance. The practical takeaway for sponsors and manufacturers: treat FDA approval as useful supporting evidence, never as a substitute for TGA assessment.
TL;DR:
- An FDA approval can accelerate evidence collection and support documentation but does not guarantee ARTG listing or registration in Australia.
- Most therapeutic goods in Australia require ARTG inclusion regardless of FDA clearance, and sponsors must meet Australian-specific requirements.
- TGA relies on overseas regulator reports and conformity assessments for medical devices, with higher risk devices subject to stricter evaluation.
- Clinical trial approval pathways differ, with Australia offering faster schemes like CTN and collaboration programs like Project Orbis to share review efforts.
- Ongoing post-market surveillance in Australia demands continuous monitoring, adverse event reporting, and traceable quality records that meet TGA standards.
The two agencies share a similar mission but operate under separate legal systems with no automatic recognition of each other’s decisions. The TGA regulates under the Therapeutic Goods Act 1989 and is responsible for medicines, medical devices and biologicals supplied in Australia, with the Therapeutic Goods Administration requiring ARTG listing or registration before most goods reach the market. The FDA operates under US federal law and has no jurisdiction over goods sold in Australia.
Work sharing exists between the two regulators. Programmes such as Project Orbis allow concurrent review of oncology medicines, letting the TGA draw on FDA assessment work while still reaching its own, separate decision.
| Dimension | TGA (Australia) | FDA (United States) |
|---|---|---|
| Legal basis | Therapeutic Goods Act 1989 | US federal law and FDA charter |
| Scope | Medicines, medical devices, biologicals | Drugs, biologic, devices, food |
| Market register | ARTG entry generally required | NDA, BLA or device clearance on file |
| Reliance tools | Comparable overseas regulator reports, Project Orbis | Leads programmes such as Orbis; does not rely on TGA decisions |
| Decision authority | Sovereign, even when using overseas data | Sovereign within US jurisdiction |
Medicines in Australia fall into three categories, each carrying a distinct label identifier. Sponsors need to know which tier applies before they can plan an evidence package or a launch date.
Sponsors in Australia carry ongoing duties regardless of category: holding evidence to support every claim, meeting advertising rules, and reporting adverse events to the TGA. An FDA approval can speed up evidence gathering and give sponsors a head start on dossier preparation, but it does not grant automatic ARTG inclusion. The Australian submission still has to stand on its own.
Device regulation in Australia follows a risk based classification system built around the Essential Principles, which set requirements for safety and performance before a device reaches the ARTG. Most devices need ARTG inclusion before supply, though the TGA accepts conformity assessment evidence from comparable overseas regulators, including FDA clearances and EU notified body certificates, to support that entry, as outlined in TGA guidance for device manufacturers.
Manufacturers planning a dual US and Australian launch typically see the biggest timeline difference at the higher risk end, where TGA conformity assessment runs independently of whatever the FDA has already decided.
Trial frameworks diverge more than most sponsors expect, and the difference affects how quickly a study can start.
Sponsors should sequence submissions deliberately: lodging with the FDA first can build an evidence base, but Australian ethics approval and site readiness usually matter more to trial timing than the regulator submission itself.
Market authorisation is the start of a sponsor’s obligations, not the end. The TGA expects ongoing monitoring, record keeping and a readiness to act on emerging safety signals, as set out in its summary of supplying therapeutic goods in Australia.
Pro Tip: Keep calibration certificates and data logger records on file alongside your quality documentation. They are often the first evidence a reviewer asks for during a post-market query.
Stakeholders facing an FDA decision and an upcoming Australian launch benefit from a clear sequence rather than assuming one approval covers both markets.
Quality systems behind an ARTG submission rely on traceable measurement. NATA accredited calibration on balances, data loggers and moisture analysers gives sponsors the kind of evidentiary record a TGA review can ask for, supporting the documentation trail that sits behind safety and quality claims.
The real risk is not misreading the FDA. It is assuming an FDA approval does the work an ARTG submission still needs. TGA sovereignty means Australian stakeholders should plan their own evidence and quality systems from the start, using FDA material as a head start rather than a shortcut. Calibration and traceable records are a practical, achievable part of that preparation.
— Kaz
Meeting TGA expectations for quality records starts with equipment you can trust. PCS Precision offers calibration services and equipment hire for sponsors who need balances, data loggers or moisture analysers on short notice. These services map directly to the records a TGA review can request: calibration certificates, traceability back to national standards, and documented maintenance history.
For manufacturers building audit ready documentation, pairing digital calibration certificates with a USP grade compliance checklist gives quality teams a practical starting point for their own evidence files. Visit our calibration services page to arrange NATA calibration or equipment hire for your next submission cycle.
This article is general information, not a substitute for advice from a qualified doctor. Consult a qualified healthcare professional about your own circumstances before acting on anything here.
No, the FDA is a United States federal agency with no jurisdiction in Australia. The Therapeutic Goods Administration is the equivalent body responsible for therapeutic goods supplied in Australia.
The Therapeutic Goods Administration is Australia’s equivalent to the FDA. It evaluates, authorises and monitors medicines, medical devices and biologicals under the Therapeutic Goods Act 1989.
The TGA regulates the Australian market under Australian law and requires most goods to be listed on the ARTG, while the FDA regulates the US market under US federal law. The two agencies sometimes collaborate through programmes such as Project Orbis, but each retains its own decision making authority.
The FDA is an American federal agency, part of the US Department of Health and Human Services. It has no regulatory authority over goods supplied in Australia.
FDA approval can support an Australian submission as supplementary evidence and may help sponsors prepare faster, but it does not replace the need for ARTG listing or registration under TGA guidance.
